Featured Story | By Nick Paul Taylor Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics—a biotech that starts life with $500 million, a collaboration with Amgen and a pipeline of eight prospects. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Bristol Myers Squibb’s deucravacitinib has hit its first bump in the road. After blowing Amgen’s Otezla away in psoriasis, deucravacitinib went into a phase 2 readout in ulcerative colitis flying high—only to fail to meet the primary or secondary endpoints. read more By Kyle LaHucik Rod MacKenzie will leave Pfizer early next year after heading up clinical development and as the company seeks expanded use of its COVID-19 vaccine. The 35-year Pfizer veteran will retire around the same time as the Big Pharma's group president John Young. read more Sponsored By: Taconic Biosciences Pressure to get results in drug discovery and development is unprecedented and the need for genetically engineered custom mouse models is greater than ever. Innovative thinking is getting these critical models into researchers hands faster. read more By Nick Paul Taylor Denali Therapeutics has set out its play for the amyotrophic lateral sclerosis (ALS) market, revealing early-phase data on one asset and plans to move a Sanofi-partnered program into phase 2 early in 2022. read more Sponsored by: Almac Group PanCan utilised Almac's IRT expertise to accelerate their adaptive platform outcomes and improve patient care. Find out how here. read more By Kyle LaHucik Joanne Chang departed Novartis after heading up worldwide medical affairs for ophthalmology for the past four years to be chief medical officer of Oculis. With a fresh set of eyes leading the medical affairs of the eye treatment biotech, Oculis will expand its presence in Hong Kong. read more By Kyle LaHucik Intergalactic Therapeutics really is shooting for the stars in its audacious mission to develop a non-viral gene therapy that doesn't require cells in the manufacturing process and can be re-dosed. The biotech's incubator, Apple Tree Partners, is pumping $75 million of rocket fuel into the biotech with a clinical telescope pointed toward ophthalmology, oncology and other potential disease targets. read more By Kyle LaHucik AffyImmune wants to avert the toxic side effects and other issues associated with CAR-T therapies using a "tune and track" approach that allows for affinity tuning and tracking of where the cells are in the body. ORI Capital is doubling down on its interest in the biotech with a $30 million second series A. read more By Angus Liu Yale University spinout Cybrexa Therapeutics has developed a peptide-drug conjugate that, instead of aiming for a specific antigen, targets the acidic environment of cancer cells to deliver a toxic payload. The drug improved the efficacy of checkpoint inhibitors in mouse models of cancer. read more By Conor Hale Calling its business model “hocus-pocus” and “a colossal scam,” activist short seller firm Scorpion Capital has stung Ginkgo Bioworks—the synthetic biology company that went public less than a month ago through a $1.6 billion SPAC deal. read more By Robert King The American Hospital Association and the U.S. Chamber of Commerce led an effort to convince lawmakers to not touch the regulatory and legal framework for reviewing mergers and acquisitions. read more By Eric Sagonowsky GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn't widely deployed. That's set to change with the World Health Organization's blessing for the vaccine. read more Resources Sponsored By: Trial Interactive Check out the eTMF Implementation Quick Guide to see a checklist TMF experts developed to help you reduce risks, maintain compliance, and establish effective processes in your eTMF. Sponsored By: Bioclinica This whitepaper addresses where AI can make the biggest impact in clinical trials. Sponsored by: Thermo Fisher Scientific Looking to accelerate your biotech company, but not sure where to start? Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: LabVantage Solutions Shift from data collection to data science. Add advanced analytics to your lab informatics platform to yield valuable, action-ready insights from LIMS and other data. Sponsored by: Thermo Fisher Scientific Integrate supply chain simulation into your early clinical trial planning to minimize risk in an uncertain supply chain environment, improve supply chain outcomes, and help streamline time-to-market for innovative therapies. Sponsored by: WCG Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
